Vytrus Biotech S.A. (VYT) - Total Assets
Based on the latest financial reports, Vytrus Biotech S.A. (VYT) holds total assets worth €11.13 Million EUR (≈ $13.01 Million USD) as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See VYT book value for net asset value and shareholders' equity analysis.
Vytrus Biotech S.A. - Total Assets Trend (2020–2024)
This chart illustrates how Vytrus Biotech S.A.'s total assets have evolved over time, based on quarterly financial data.
Vytrus Biotech S.A. - Asset Composition Analysis
Current Asset Composition (December 2024)
Vytrus Biotech S.A.'s total assets of €11.13 Million consist of 34.1% current assets and 65.9% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 22.7% |
| Accounts Receivable | €617.79K | 5.6% |
| Inventory | €519.29K | 4.7% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €4.08 Million | 36.6% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Vytrus Biotech S.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see VYT market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vytrus Biotech S.A.'s current assets represent 34.1% of total assets in 2024, an increase from 24.8% in 2020.
- Cash Position: Cash and equivalents constituted 22.7% of total assets in 2024, up from 17.6% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 36.0% of total assets, a decrease from 40.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 36.6% of total assets.
Vytrus Biotech S.A. Competitors by Total Assets
Key competitors of Vytrus Biotech S.A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.62 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥7.26 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥38.02 Billion |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180
|
China | CN¥11.69 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $504.60 Million |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $563.83 Million |
Vytrus Biotech S.A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.03 | 2.21 | 2.21 |
| Quick Ratio | 2.61 | 1.72 | 1.72 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €2.54 Million | €1.02 Million | €1.02 Million |
Vytrus Biotech S.A. - Advanced Valuation Insights
This section examines the relationship between Vytrus Biotech S.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.25 |
| Latest Market Cap to Assets Ratio | 7.98 |
| Asset Growth Rate (YoY) | 19.5% |
| Total Assets | €11.13 Million |
| Market Capitalization | $88.79 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Vytrus Biotech S.A.'s assets at a significant premium (7.98x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Vytrus Biotech S.A.'s assets grew by 19.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Vytrus Biotech S.A. (2020–2024)
The table below shows the annual total assets of Vytrus Biotech S.A. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €11.13 Million ≈ $13.01 Million |
+19.50% |
| 2023-12-31 | €9.31 Million ≈ $10.89 Million |
+16.38% |
| 2022-12-31 | €8.00 Million ≈ $9.36 Million |
+11.43% |
| 2021-12-31 | €7.18 Million ≈ $8.40 Million |
+15.69% |
| 2020-12-31 | €6.21 Million ≈ $7.26 Million |
-- |
About Vytrus Biotech S.A.
Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. The company offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Ca… Read more